Ir a las Transacciones
Salud

Laboratorios Saval S.A. has acquired a pharmeceutical processing plant

Laboratorios Saval S.A. has acquired a pharmeceutical processing plant in Costa Rica from Laboratorios Stein S.A.

Laboratorios Saval is a Chilean company with more than 80 years of history. It began its history in Spain in the 1930s and today, has a presence in more than 14 countries. The company manufactures and distributes pharmaceuticals in the areas of infectious diseases, ophthalmology, immunology and oncology, gastroenterology, bronchopulmonary, cardiology, psychiatry and rheumatology.

Laboratorios Stein is a leading company in Latin America in the commercialization and distribution of highly complex pharmaceutical products including innovative products, biosimilars and complex generics.

Oaklins’ team in Chile acted as financial advisor to Laboratorios Saval in this transaction.

PARTES

Contáctese con el equipo de la transacción

Felipe Porzio

Managing Partner
Santiago, Chile
Oaklins LarrainVial

Agustin Achondo

Director
Santiago, Chile
Oaklins LarrainVial

Alberto Parot

Analista
Santiago, Chile
Oaklins LarrainVial

Transacciones relacionadas

Leika Medical Equipments Ltd. has been acquired by Angus Capital
Private Equity | Salud

Leika Medical Equipments Ltd. has been acquired by Angus Capital

The shareholders of Leika Medical Equipments Ltd. have sold the company to Angus Capital.

Ver más
Phen’X Technologies has sold a majority stake to Ciclad
Private Equity | Salud | Maquinaria y Componentes Industriales

Phen’X Technologies has sold a majority stake to Ciclad

The shareholders of Phen’X Technologies have completed a primary majority LBO with private equity fund Ciclad.

Ver más
Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments
Salud | TMT

Medis Medical Imaging and GE HealthCare announce collaboration focused on non-invasive coronary assessments

Medis Medical Imaging Systems B.V., a leading cardiac imaging software company, have completed a strategic investment to further develop its revolutionary non-invasive cardiovascular imaging solution. The company has announced its collaboration with GE HealthCare (Nasdaq: GEHC), a global leader in medical technology, pharmaceutical diagnostics and innovation in digital solutions, to contribute to the advancement of precision care in the diagnosis and treatment of coronary artery disease (CAD).

Ver más